Carlyle Said Close to Buying J&J Diagnostics Unit

Private equity investor Carlyle is in exclusive talks to buy Johnson & Johnson's ortho clinical diagnostics unit for around $4 billion, after knocking Blackstone out of the race, financial market reports said shortly before Christmas. A deal was expected to be concluded in the first half of January.

The unit, described as a small player in a market dominated by larger companies such as Roche, Siemens, Abbott and Danaher, manufactures blood-screening equipment and laboratory blood tests as well as tests capable of identifying blood types and screening for viruses such as HIV and hepatitis C.

At the beginning of 2013, Johnson & Johnson had said it was exploring strategic alternatives for business, a process that could take 12-24 months. Blackstone was reportedly bidding in cooperation with Danaher.

Innovation Pitch

The Start-up Platform for Chemistry & Life Sciences
Discover Tomorrow’s Innovators

The Start-up Platform for Chemistry & Life Sciences

CHEManager Innovation Pitch supports innovation in the chemistry and life sciences start-up scene. The platform allows founders, young entrepreneurs, and start-ups to present their companies to the industry.

Interview

Stability in Motion
Strategic Response to a Shifting Pharma Landscape

Stability in Motion

Stefan Oelrich, Member of the Board of Management and President Pharmaceuticals, Bayer, discusses navigating external volatility, reshaping its internal structures, and investing in future-ready capabilities to ensure sustainable growth.

most read

Photo
28.07.2025 • NewsChemistry

VCI Welcomes US-EU Customs Deal

The German Chemical Industry Association (VCI) welcomes the fact that Ursula von der Leyen, President of the European Commission, and US President Donald Trump have averted the danger of a trade war for the time being.